• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文OA文献 >”Biweekly oxaliplatin combined with ral Capecitabine (OXXEL regimen) as first-line treatment of metastatic colorectal cancer patients. A Southern Italy Cooperative Oncology Group phase II study”
【2h】

”Biweekly oxaliplatin combined with ral Capecitabine (OXXEL regimen) as first-line treatment of metastatic colorectal cancer patients. A Southern Italy Cooperative Oncology Group phase II study”

机译：每两周一次奥沙利铂联合拉非卡培他滨（OXXEL方案）作为转移性结直肠癌患者的一线治疗。意大利南部合作肿瘤学小组第二阶段研究”

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Oxaliplatin 100 mg/m2 iv on day 1, and capecitabine 1,000 mg/m2 orally bid from day 1 (evening) to day 11 (morning) were administered every 2 weeks (OXXEL regimen) to 38 patients as first-line treatment for metastatic colorectal carcinoma. A total of 318 cycles were administered, with a median of 8 (range, 4-12) cycles per patient. Response rate (RR) was 45% (95% confidence interval (CI), 29%-62%), with 7 complete responses and 10 partial responses; furthermore, 12 patients showed a stable disease, so that a disease control was achieved in 29 (76%) patients. RR was greater among patients with performance status 0 (52%), without weight loss (52%), younger than 65 years (50%), and previously unexposed to adjuvant chemotherapy (48%), while no correlation was found with the actually delivered oxaliplatin dose intensity. Overall, haematological side effects were negligible, with no case of grade 4 toxicity, and only one patient suffering from an episode of grade 3 neutropenic fever. Severe anaemia occurred in 4 (11%) patients, and grade 3 neuropathy affected 9 (24%) patients. Median progression-free survival was 7.9 (95% CI, 6.2-9.6) months, and median overall survival has not been reached yet. In conclusion, the OXXEL regimen resulted safe and active, and it deserves further evaluation in metastatic colorectal cancer patients.
机译：第1天（晚上）至第11天（早上）第1天静脉输注奥沙利铂100 mg / m2，从第1天（晚上）至第11天（早晨）口服卡培他滨1,000 mg / m2，作为转移性结直肠癌的一线治疗方法（共38例）癌。总共进行了318个周期的治疗，每位患者的中位数为8个（范围4-12）个周期。缓解率（RR）为45％（95％置信区间（CI），29％-62％），其中7例为完全缓解，10例为部分缓解；此外，有12位患者表现出稳定的疾病，因此有29位（76％）患者实现了疾病控制。表现状态为0（52％），未减轻体重（52％），65岁以下（50％）且以前未接受过辅助化疗（48％）的患者中，RR较高。递送奥沙利铂剂量强度。总体而言，血液学副作用可忽略不计，没有4级毒性病例，只有一名患者发生3级中性粒细胞减少。严重贫血发生在4名（11％）患者中，并且3级神经病变影响了9名（24％）患者。中位无进展生存期为7.9（95％CI，6.2-9.6）个月，尚未达到中位总体生存期。总之，OXXEL方案安全，有效，在转移性结直肠癌患者中值得进一步评估。

著录项

相似文献

  • 外文文献
  • 中文文献
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号